Novavax (NASDAQ:NVAX) Trading Down 8%

Novavax, Inc. (NASDAQ:NVAXGet Rating)’s share price dropped 8% during trading on Tuesday . The stock traded as low as $50.73 and last traded at $50.77. Approximately 35,335 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 5,004,428 shares. The stock had previously closed at $55.16.

NVAX has been the topic of a number of recent analyst reports. Jefferies Financial Group initiated coverage on Novavax in a research report on Tuesday, February 22nd. They set a “buy” rating and a $198.00 target price on the stock. StockNews.com initiated coverage on Novavax in a research report on Thursday, March 31st. They set a “hold” rating on the stock. B. Riley decreased their target price on Novavax from $265.00 to $250.00 in a research report on Wednesday, March 2nd. Cantor Fitzgerald decreased their target price on Novavax from $282.00 to $174.00 and set an “overweight” rating on the stock in a research report on Monday, February 14th. Finally, HC Wainwright decreased their target price on Novavax from $294.00 to $207.00 and set a “buy” rating on the stock in a research report on Thursday, March 3rd. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Novavax presently has an average rating of “Buy” and a consensus target price of $204.86.

The firm has a market capitalization of $4.21 billion, a price-to-earnings ratio of -2.19 and a beta of 1.34. The business has a 50 day simple moving average of $75.55 and a 200-day simple moving average of $124.95. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.90 and a current ratio of 0.90.

Novavax (NASDAQ:NVAXGet Rating) last issued its earnings results on Monday, February 28th. The biopharmaceutical company reported ($11.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($9.75). Novavax had a negative return on equity of 368.20% and a negative net margin of 152.12%. The company had revenue of $222.20 million during the quarter, compared to analyst estimates of $331.79 million. During the same period last year, the business earned ($2.70) earnings per share. The firm’s revenue was down 20.5% compared to the same quarter last year. Equities analysts predict that Novavax, Inc. will post 22.84 earnings per share for the current fiscal year.

In related news, Director James F. Young sold 12,500 shares of the firm’s stock in a transaction dated Thursday, March 31st. The stock was sold at an average price of $73.58, for a total transaction of $919,750.00. Following the completion of the sale, the director now directly owns 62,590 shares of the company’s stock, valued at approximately $4,605,372.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Spire Wealth Management increased its position in shares of Novavax by 186.7% during the 4th quarter. Spire Wealth Management now owns 172 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 112 shares during the last quarter. Selective Wealth Management Inc. acquired a new stake in shares of Novavax during the 4th quarter worth about $29,000. DB Wealth Management Group LLC acquired a new position in Novavax in the 4th quarter valued at about $29,000. FUKOKU MUTUAL LIFE INSURANCE Co grew its position in Novavax by 40.0% in the 3rd quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 280 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 80 shares in the last quarter. Finally, TCI Wealth Advisors Inc. grew its position in Novavax by 115.7% in the 4th quarter. TCI Wealth Advisors Inc. now owns 289 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 155 shares in the last quarter. 47.38% of the stock is owned by hedge funds and other institutional investors.

Novavax Company Profile (NASDAQ:NVAX)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Read More

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.